2076975 2077203
최종편집 2024-06-24 07:03 (월)
Multinational pharmaceutical company’s subsidiaries in Korea, the average COGS ratio approaches 80%
상태바
Multinational pharmaceutical company’s subsidiaries in Korea, the average COGS ratio approaches 80%
  • Hyeokgi Lee, Newsmp
  • 승인 2022.04.19 10:34
  • 댓글 0
이 기사를 공유합니다

Roche 90.1%, Pfizer 89.9%... average of 33 companies 76.0%

[Newsmp] The cost of goods sold ratio (COGS) of multinational pharmaceutical companies’ subsidiaries in Korea was close to the 80% mark on average.

Pfizer Pharmaceutical Korea, which has greatly is sales with the influence of the COVID-19 vaccine, has raised the average COGS ratio of multination pharmaceutical companies significantly as its COGS soared due to benefits in return.

Newsmp tallied the results of the COGS ratio of 33 multinational pharmaceutical companies, whose closing accounts are between September and December, and found that it increased by 4.0%p from an average of 72.0% in 2020 to 76.0% last year.

Among them, except for Pfizer Pharmaceutical Korea, Janssen Vaccine, which did not generate sales last year, and the start-up company Organon Korea, the average COGS ratio of the remaining 30 companies rose 0.3%p from 71.5% to 71.8%, showing no significant change.

By company, out of 31 companies excluding Organon and Janssen Vaccine, the cost ratio of 15 companies rose while 14 companies decreased.

Allergan Korea’s COGS ratio jumped 17.8%p from 2020, Pfizer Pharmaceutical Korea’s 14.9%p, and Roche Korea’s 9.0%p.

The COGS of Sanofi Pasteur, Alcon Korea, Lilly Korea, AstraZeneca Korea, and Sanofi-Aventis also increased by more than 5%.

On the other hand, the COGS of GSK decreased by 12.9%p and that of MSD Korea dropped by 9.10%p during the same period.

In 2021, Roche Korea was the only one to exceed the 90% mark with 90.1%, followed by Pfizer Pharmaceutical Korea with 89.9%.

Boehringer Ingelheim Korea maintained the 80% mark with 81.1%, and the three companies recorded a COGS ratio of more than 80%.

Celgene Korea, Korea UCB, Novo Nordisk, Novartis Korea, AstraZeneca Korea, and Sanofi Pasteur showed higher than average COGS (76.0%), while Organon Korea, Viatris Korea, Guerbet Korea, Lundbeck Korea, Ferring Korea, Sanofi-Aventis, Biogen Korea, Lilly Korea, Kyowa Kirin Korea, and MSD Korea exceeded the 70% mark.

Nearly two-thirds of the 33 companies recorded a COGS ratio of more than 70%.

In addition, Bayer Korea, Alcon Korea, AbbVie Korea, Allergan Korea, Fresenius Kabi Korea, BMS Korea, Servier Korea, and GSK Consumer Healthcare Korea reached a COGS ratio of 60% level, while GSK, Mundipharma Korea, Galderma Korea, and Korea Otsuka Pharmaceuticals were counted in the 50% mark, Menarini Korea was the only company to fall below 50%.


 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.